抗生素和抗真菌药市场分析及预测(按规模、份额、增长、趋势)2031 年

  • Report Code : TIPRE00021878
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 203
Buy Now

Antibiotics and Antimycotics Market Size and CAGR by 2031

Buy Now

抗生素和抗真菌药物市场规模预计将从 2023 年的 612.0798 亿美元增至 2031 年的 915.4607 亿美元。预计 2023-2031 年期间市场复合年增长率将达到 5.2%。产品开发和治疗方法的技术进步可能会在未来几年为抗生素和抗真菌药物市场带来新趋势。

抗生素和抗真菌药市场分析

推动抗生素和抗真菌剂市场发展的因素包括细菌和真菌引起的传染病日益流行,以及人们对真菌感染的认识不断提高。产品发布和批准等战略举措不断涌现,再加上各政府和公共组织的举措,预计将推动未来市场的增长。此外,持续的资金投入和研发举措预计将在未来几年促进市场发展。

抗生素和抗真菌药市场概况

北美主导着抗生素和抗真菌药市场。由于细菌和真菌感染(如肺炎、尿路感染 (UTI)、性传播疾病和皮肤感染)在亚太地区的流行率不断上升,预计未来几年亚太地区的市场将出现显著增长。此外,市场参与者的产品发布、产品审批和开发等战略举措可能会为未来几年的市场增长提供丰厚的机会。

中国正经历着真菌和细菌感染(如尿路感染、肺炎和呼吸道感染)的激增,这反过来又产生了对抗生素和抗真菌药物的需求,用于治疗和管理这些疾病。根据《流行病学与感染杂志》的报道,2023 年,中国每年约有 2110 万人患社区获得性肺炎 (CAP)。此外,包括细菌、真菌和病毒在内的各种病原体占儿童急性呼吸道感染的 80%。该国常用的抗生素包括青霉素、氟喹诺酮类、头孢菌素和硝基咪唑类。

定制研究以满足您的需求

我们可以优化和定制标准产品无法满足的分析和范围。这种灵活性将帮助您获得业务规划和决策所需的准确信息。

抗生素和抗真菌剂市场:

抗生素和抗真菌药市场
  • Antibiotics and Antimycotics Market
    复合年增长率(2023 - 2031)
    5.2%
  • 2023 年市场规模
    612.0798 亿美元
  • 市场规模 2031
    915.4607 亿美元

市场动态

增长动力
  • 传染病发病率上升有利于市场增长
未来趋势
  • 产品开发和治疗方法的技术进步预计将成为未来几年的趋势
机会
  • 持续的资金和研发计划很可能在未来几年创造充足的机会

关键参与者

  •  
  • 辉瑞公司
  • 诺华公司
  • 赛诺菲公司
  • F霍夫曼拉罗氏有限公司
  • 默克公司
  • 葛兰素史克公司
  • 約翰遜 約翰遜
  • 西普拉有限公司
  • 拜耳公司

区域概况

Antibiotics and Antimycotics Market
  • 北美
  • 欧洲
  • 亚太
  • 南美洲和中美洲
  • 中东和非洲

市场细分

Antibiotics and Antimycotics Market药物类别
  • 青霉素
  • 头孢菌素
  • 卡巴培南类
  • 大环内酯类
  • 氨基糖苷类
  • 喹诺酮类
  • 磺胺类药物
  • 四环素类
  • 唑类
Antibiotics and Antimycotics Market指征
  • 皮肤感染
  • 呼吸道感染
  • 泌尿道感染
  • 败血症
  • 耳部感染
  • 胃肠道感染
Antibiotics and Antimycotics Market给药途径
  • 口服
  • 主题
Antibiotics and Antimycotics Market分销渠道
  • 医院药房
  • 零售药店和药店
  • 网上药店
  • 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。

抗生素和抗真菌剂市场驱动因素和机遇

传染病患病率上升推动市场增长

传染病是由细菌、病毒、寄生虫、真菌和有毒物质引起的。根据 ReAct Group 2022 年的报告,全球报告的 7700 万例死亡病例(占总死亡人数的 13.6%)与细菌感染有关,但不包括结核病。根据世界卫生组织 (WHO) 的数据,结核病 (TB) 是全球第 13 大死因,是继 COVID-19 之后第二大最常见的传染病。根据世卫组织的数据,2022 年有 130 万人(包括 21.4 万艾滋病毒感染者)死于结核病。其估计还指出,2022 年全球有 1060 万人患有结核病,其中包括 130 万名儿童、350 万名女性和 580 万名男性。30 个结核病负担高的国家占当年新发结核病病例的 86-90%。八个国家占总数的三分之二,其中印度居首,其次是菲律宾、中国、印度尼西亚、巴基斯坦、尼日利亚、孟加拉国和南非。利福平、异烟肼、吡嗪酰胺和乙胺丁醇是美国 FDA 批准用于治疗结核分枝杆菌感染的主要抗生素。

此外,真菌感染的增多是全球广大民众的主要担忧之一。根据全球真菌感染行动基金 (GAFFI) 2024 年的数据,每年有超过 8000 万人面临患真菌病的高风险,每年约有 655 万患者患上危及生命的真菌感染,其中 375 万人死亡。唑类和两性霉素 B 是全球用于治疗真菌感染的几种常见抗真菌药物。因此,全球各种细菌和真菌相关传染病的流行率不断上升,对抗生素和抗真菌药物的需求巨大。

持续的资金和研发计划创造增长机会

抗生素和抗真菌药市场中的公司正在不断努力开发新产品或更新现有产品,并为药物开发和临床研究筹集资金。私人和政府组织的倡议和支持也推动了抗生素和抗真菌药的发展。下面提到了近年来市场上发生的一些最新发展。

  • 2024年9月,英国生物制药公司F2G完成1亿美元融资,用于进行用于治疗侵袭性曲霉病和其他侵袭性真菌感染的新型口服抗真菌疗法olorofim的后期开发和商业化。
  • 2024 年 6 月,全球抗生素研究与开发伙伴关系 (GARDP) 和 Bugworks Research Inc (Bugworks) 签署了一项合作协议,共同开发一种名为 BWC0977 的创新化合物。该候选药物对导致危及生命的感染的多重耐药细菌表现出广谱抗生素活性。
  • 2023 年 6 月,BioVersys 成为第一家通过 AMR 行动基金获得临床试验资金的欧洲公司。该基金是全球第二大促进医学研究的基金会;预计到 2030 年,它将支持推出 2-4 种抗菌药物,以对抗细菌耐药性。
  • 2022 年 10 月,CARB-X 启动新一轮融资,目标是重点关注预防、诊断和治疗新生儿败血症、淋病和抗菌素耐药细菌引起的感染等关键全球卫生需求。

因此,预计公司和学术组织持续的资金投入和研发计划将为未来几年抗生素和抗真菌药物市场的增长创造充足的机会。

抗生素和抗真菌药市场报告细分分析

有助于抗生素和抗真菌药市场分析的关键部分是药物类别、适应症、给药途径和分销渠道。

  • 根据药物类别,抗生素和抗真菌药市场分为青霉素、头孢菌素、卡巴培南类、大环内酯类、氨基糖苷类、喹诺酮类、磺胺类、四环素类、唑类等。青霉素类在 2023 年占据了最大的市场份额,而头孢菌素类预计在 2023-2031 年期间将实现最高的复合年增长率。
  • 根据适应症,抗生素和抗真菌药市场分为皮肤感染、呼吸道感染、尿路感染、败血症、耳部感染、胃肠道感染等。2023 年,皮肤感染部分占据了最大的市场份额。预计呼吸道感染部分将在 2023-2031 年期间实现最高的复合年增长率。
  • 根据给药途径,抗生素和抗真菌药市场分为口服、外用和其他。口服部分在 2023 年占据了最大的市场份额。预计其他部分将在 2023-2031 年期间实现最高的复合年增长率。
  • 就分销渠道而言,抗生素和抗真菌药市场分为医院药房、零售药房和药店以及在线药房。医院药房部分在 2023 年占据市场主导地位,预计在线药房部分在 2023-2031 年期间的复合年增长率最高。

抗生素和抗真菌药物市场份额按地区分析

抗生素和抗真菌药市场报告的地理范围主要分为五个地区:北美、亚太地区、欧洲、中东和非洲以及南美和中美洲。北美在 2023 年占据了相当大的市场份额。该地区市场的增长归因于细菌和真菌感染的患病率不断上升,以及发达的医疗保健基础设施和各种抗生素和抗真菌药的可用性。此外,预计主要参与者的产品发布、批准和其他战略举措的增加将在预测期内为市场增长创造机会。美国抗生素和抗真菌药市场的增长是由真菌和细菌感染的患病率不断上升推动的,这导致对有效治疗方案的需求明显增加。肺炎是美国最常见的呼吸道感染。根据 Verywell Health Journal 2024 的报告,每年,美国约有 150 万成年人被诊断出患有肺炎;其中约 100 万人入院,而 50,000 人死于该病或相关并发症。阿莫西林和阿奇霉素是美国门诊治疗细菌感染最常用的抗生素。此外,随着药物研究和技术的不断进步,新型抗生素和抗真菌剂的开发势头强劲,以应对人们对抗生素耐药性的日益担忧和对创新疗法的需求。

抗生素和抗真菌药市场报告范围

报告属性细节
2023 年的市场规模612.0798亿美元
2031 年市场规模915.4607 亿美元
全球复合年增长率(2023 - 2031)5.2%
史料2021-2022
预测期2024-2031
涵盖的领域按药物类别
  • 青霉素
  • 头孢菌素
  • 卡巴培南类
  • 大环内酯类
  • 氨基糖苷类
  • 喹诺酮类
  • 磺胺类药物
  • 四环素类
  • 唑类
按适应症
  • 皮肤感染
  • 呼吸道感染
  • 泌尿道感染
  • 败血症
  • 耳部感染
  • 胃肠道感染
按给药途径
  • 口服
  • 主题
按分销渠道
  • 医院药房
  • 零售药店和药店
  • 网上药店
覆盖地区和国家北美
  • 我们
  • 加拿大
  • 墨西哥
欧洲
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 意大利
  • 欧洲其他地区
亚太
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
南美洲和中美洲
  • 巴西
  • 阿根廷
  • 南美洲和中美洲其他地区
中东和非洲
  • 南非
  • 沙特阿拉伯
  • 阿联酋
  • 中东和非洲其他地区
市场领导者和主要公司简介
  •  
  • 辉瑞公司
  • 诺华公司
  • 赛诺菲公司
  • F霍夫曼拉罗氏有限公司
  • 默克公司
  • 葛兰素史克公司
  • 約翰遜 約翰遜
  • 西普拉有限公司
  • 拜耳公司
  • 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。

抗生素和抗真菌剂市场新闻和最新发展

抗生素和抗真菌药市场通过收集一级和二级研究后的定性和定量数据进行评估,其中包括重要的公司出版物、协会数据和数据库。抗生素和抗真菌药市场的一些发展情况如下:

  • 辉瑞公司获得欧盟委员会 (EC) 的 EMBLAVEO(阿曲南-阿维巴坦)上市许可,用于治疗患有复杂性腹腔内感染、医院获得性肺炎和复杂性尿路感染的成人患者。该药物还可用于治疗治疗选择有限的成人患者中需氧革兰氏阴性菌引起的感染。EMBLAVEO 是欧盟批准的首个 β-内酰胺/β-内酰胺酶抑制剂抗生素组合。(来源:辉瑞公司,公司网站,2024 年 4 月)
  • Orchid Pharma 推出了其新的头孢吡肟-恩美唑巴坦药物,该药物已被批准用于治疗复杂性尿路感染、医院获得性肺炎和呼吸机相关性肺炎。在一次具有里程碑意义的合作中,Orchid Pharma 与 Cipla Limited 合作,确保这种突破性的抗生素组合在印度广泛而迅速地分发。(来源:Cipla Ltd,公司网站,2024 年 6 月)

抗生素和抗真菌剂市场报告覆盖范围和交付成果

“抗生素和抗真菌药市场规模和预测(2021-2031 年)”报告对以下领域进行了详细的市场分析:

  • 抗生素和抗真菌药物的市场规模以及全球、区域和国家层面所有主要细分市场的预测
  • 抗生素和抗真菌药物的市场趋势,以及市场动态,如驱动因素、限制因素和关键机遇
  • 详细的 PEST 和 SWOT 分析
  • 抗生素和抗真菌药物市场分析涵盖主要市场趋势、全球和区域框架、主要参与者、法规和最新市场发展
  • 行业格局和竞争分析,涵盖市场集中度、热图分析、知名参与者以及抗生素和抗真菌药物市场的最新发展
  • 详细的公司简介

 

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Which region dominated the antibiotics and antimycotics market in 2023?

North America dominated the antibiotics and antimycotics market in 2023.

Which are the leading players operating in the antibiotics and antimycotics market?

Pfizer Inc, Novartis AG, Sanofi SA, F. Hoffmann-La Roche Ltd, Merck & Co Inc, GSK Plc, Johnson & Johnson, Cipla Ltd, Bayer AG, AbbVie Inc, and Astellas Pharma Inc. are among the key players operating in the antibiotics and antimycotics market.

What are the factors driving the antibiotics and antimycotics market growth?

The increasing prevalence of infectious diseases and growing awareness about fungal infections are the common factors fueling the market growth.

What is the expected CAGR of the antibiotics and antimycotics market?

The antibiotics and antimycotics market is estimated to register a CAGR of 5.2% during the forecast period.

What would be the estimated value of the antibiotics and antimycotics market by 2031?

The antibiotics and antimycotics market value is estimated to reach US$ 91,546.07 million by 2031.

The List of Companies - Antibiotics and Antimycotics Market

  1. Pfizer Inc 
  2. Novartis AG 
  3. Sanofi SA
  4. F. Hoffmann-La Roche Ltd
  5. Merck & Co Inc 
  6. GSK Plc
  7. Johnson & Johnson
  8. Cipla Ltd
  9. Bayer AG 
  10. AbbVie Inc 
  11. Astellas Pharma Inc

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Pharmaceuticals : READ MORE..